Table 2.
The MET status and efficacy of ABN401 in cancer cell lines and patient-derived xenograft (PDX) models.
| Group | Name | MET CNV | c-MET IHC | MET FISH | ABN401 Dose (mg/kg) |
TGI (%) |
||
|---|---|---|---|---|---|---|---|---|
| q-PCR | WES * | C | M | MET/CEP7 Ratio | ||||
| Xenograft (MET-high amplification) |
SNU5 | 18.6 | 3 | 3 | >5 | 3 | 24.47 | |
| 30 | 89.49 | |||||||
| EBC-1 | 17.25 | 3 | 3 | >5 | 10 | 51.26 | ||
| 30 | 77.85 | |||||||
| Xenograft (c-MET overexpression) |
SNU638 | 2.26 | 3 | 3 | 0.8 | 10 | 65.31 | |
| 30 | 78.68 | |||||||
| Patient-derived Xenograft (MET-negative) |
GA2278 | 1 | 0 | 0 | 0.8 | 10 | 56.0 | |
| 30 | 47.6 | |||||||
| Patient-derived Xenograft (MET-low amplification) |
GA0075 | 5 | 0 | 0 | 0.6 | 10 | 16.2 | |
| 30 | 22.3 | |||||||
| GA0152 | 5 | 0 | 0 | 0.8 | 10 | 7.4 | ||
| 30 | 14.2 | |||||||
| GA0046 | 5 | 1 | 1 | 1 | 10 | 17.3 | ||
| 30 | 13.4 | |||||||
| Patient-derived Xenograft (MET-mid amplification) |
LU5381 (+MET exon14 Skipping) |
5 | 3 | 3 | 2.05 | 10 | 63.09 | |
| 30 | 75.47 | |||||||
| Patient-derived Xenograft (MET-high amplification) |
LU2503 (+METex14 skipping) |
14 | 3 | 3 | >5 | 10 | 96.75 | |
| 30 | 99.11 | |||||||
| GA3121 | 14 | 3 | 3 | >10 | 10 | 89.8 | ||
| 30 | 102.4 | |||||||
| LI0612 | 14 | 3 | 3 | >10 | 10 | 86.6 | ||
| 30 | 109.1 | |||||||
CNV = copy number variation, q-PCR = quantitative PCR, WES = whole exome sequencing, C = cytosol, M = membrane, TGI = tumor growth inhibition. * MET copy number of PDX models was obtained using WES by Crownbio.